Website

ChromaDex Corporation (CDXC) is a Medicinal Chemicals and Botanical Products company listed on NASDAQ. There were no new wire items for CDXC in the last 30 days. The most recent was published Mar 19, 2025.

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Latest news

25 items

CDXC FAQ

7 questions
  • What does ChromaDex Corporation do?
    ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also...
  • What is the latest news on CDXC?
    Quantisnow has not tracked any new filings, ratings or press releases for CDXC in the last 30 days. The most recent wire item was published on March 19, 2025.
  • Where does CDXC stock trade?
    ChromaDex Corporation (CDXC) is listed on NASDAQ.
  • What sector and industry is CDXC in?
    ChromaDex Corporation operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.
  • What are analysts saying about CDXC?
    Across the last 5 analyst actions on ChromaDex Corporation, there were 0 upgrades and 2 downgrades. The most recent action was from Oppenheimer: Perform on 2022-08-16. Recent price targets range from $2.40 to $12.00.
  • What companies are similar to CDXC?
    Notable peers in the same industry include SMFL (Smart for Life Inc.), VLON (Vallon Pharmaceuticals Inc.), MNMD (Mind Medicine (MindMed) Inc.), GRPH (Graphite Bio Inc.), SISI (Shineco Inc.). Compare CDXC side-by-side with any of them on Quantisnow.
  • How can I track CDXC on Quantisnow?
    Quantisnow aggregates ChromaDex Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDXC to receive live email and push alerts on every new disclosure.